Could a new combo drug help with Schizophrenia's 'Negative' symptoms?

NCT ID NCT02477670

Completed Symptom relief Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tested whether AVP-786, a combination of two drugs, can reduce negative symptoms (like lack of emotion or motivation) in people with schizophrenia. 145 adults on stable antipsychotics received either AVP-786 or a placebo for 12 weeks. The study measured changes in symptom scales to see if the drug helps where current treatments fall short.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AVP-786 (deuterated dextromethorphan/quinidine)
What this could lead to: If it works, this could offer a new option to ease negative symptoms like social withdrawal and lack of motivation in people with schizophrenia.
What could go wrong: This is an early Phase 2 trial with only 145 people, so results may not apply broadly. The drug may not work better than placebo or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Study site

Cerritos, California, United States
Study site

Garden Grove, California, United States
Study site

National City, California, United States
Study site

Oakland, California, United States
Study site

San Diego, California, United States
Study site

Washington D.C., District of Columbia, United States
Study site

Orlando, Florida, United States
Study site

Atlanta, Georgia, United States
Study site

Augusta, Georgia, United States
Study site

Chicago, Illinois, United States
Study site

Boston, Massachusetts, United States
Study site

Worcester, Massachusetts, United States
Study site

Grand Rapids, Michigan, United States
Study site

Marlton, New Jersey, United States
Study site

Jamaica, New York, United States
Study site

New York, New York, United States
Study site

Rochester, New York, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.